Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18

Graham L. Cohen, Corlia Coetzee, Cathryn A. Walton, Òscar Reig Torras, Byoung Chul Cho, Georgina McAdam, Carlos I. Rojas, Laura Medina Rodríguez, Zsuzsanna Papai, Sze W. Chan, Bernardo L. Rapoport, Christian Caglevic, Patricio Yañez Weber, Toshiaki Takahashi, Takayasu Kurata, Gina Song, Julia W. Cohen, Omobolaji O. Akala, Richard Khanyile

Open source

DOI: 10.1016/j.ejca.2025.115709
Published: 2025-11
Container: European Journal of Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.115709,
  title = {Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18},
  author = {Graham L. Cohen and Corlia Coetzee and Cathryn A. Walton and Òscar Reig Torras and Byoung Chul Cho and Georgina McAdam and Carlos I. Rojas and Laura Medina Rodríguez and Zsuzsanna Papai and Sze W. Chan and Bernardo L. Rapoport and Christian Caglevic and Patricio Yañez Weber and Toshiaki Takahashi and Takayasu Kurata and Gina Song and Julia W. Cohen and Omobolaji O. Akala and Richard Khanyile},
  year = {2025},
  journal = {European Journal of Cancer},
  doi = {10.1016/j.ejca.2025.115709},
  url = {https://doi.org/10.1016/j.ejca.2025.115709}
}

RIS

TY  - JOUR
TI  - Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18
AU  - Graham L. Cohen
AU  - Corlia Coetzee
AU  - Cathryn A. Walton
AU  - Òscar Reig Torras
AU  - Byoung Chul Cho
AU  - Georgina McAdam
AU  - Carlos I. Rojas
AU  - Laura Medina Rodríguez
AU  - Zsuzsanna Papai
AU  - Sze W. Chan
AU  - Bernardo L. Rapoport
AU  - Christian Caglevic
AU  - Patricio Yañez Weber
AU  - Toshiaki Takahashi
AU  - Takayasu Kurata
AU  - Gina Song
AU  - Julia W. Cohen
AU  - Omobolaji O. Akala
AU  - Richard Khanyile
PY  - 2025
JO  - European Journal of Cancer
DO  - 10.1016/j.ejca.2025.115709
UR  - https://doi.org/10.1016/j.ejca.2025.115709
ER  -

APA

Cohen, G. L., Coetzee, C., Walton, C. A., Torras, Ò. R., Cho, B. C., McAdam, G., Rojas, C. I., Rodríguez, L. M., Papai, Z., Chan, S. W., Rapoport, B. L., Caglevic, C., Weber, P. Y., Takahashi, T., Kurata, T., Song, G., Cohen, J. W., Akala, O. O., & Khanyile, R. (2025). Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115709

Source records

crossref · retrieved 2026-09-25T10:23:22.313Z